Low-grade chronic inflammation is increasingly recognized as a contributor to multiple long-term diseases, including obesity, cardiovascular disease, diabetes and cancer. The concept of scoring the inflammatory potential of dietary patterns aims to provide an objective measure that links habitual diet to inflammatory biomarker profiles and downstream disease risk. This review examines the development, current evidence, and potential clinical applications of the Dietary Inflammatory Index (DII) as a tool for nutritional assessment and disease prevention.
The DII was created to quantify the inflammatory effects of diet using literature-derived associations between specific dietary components and inflammatory biomarkers. It produces a score that reflects the overall inflammatory potential of an individual’s dietary pattern. The index is intended for use in population and clinical research to characterize diet–inflammation relationships and to identify dietary patterns associated with higher or lower systemic inflammation.
Recent studies summarized in the review report consistent associations between higher (more proinflammatory) DII scores and adverse cardiometabolic outcomes. These associations include links to subclinical atherosclerosis, clinical atherosclerotic disease, metabolic liver disease, obesity, and elevated cardiovascular mortality. The review highlights that across different cohorts and study designs, higher DII values tend to correlate with poorer metabolic profiles and increased risk markers related to cardiovascular health.
Dietary patterns known for anti-inflammatory effects, particularly the Mediterranean diet, are consistently associated with lower DII scores. Lower DII scores in these contexts have been linked to reductions in inflammatory biomarkers, improvements in metabolic parameters, and better reported quality of life. The review indicates that adopting anti-inflammatory dietary patterns corresponds to measurable changes in DII and associated biomarker improvements, supporting the DII’s construct validity in capturing dietary influences on inflammation.
Beyond cardiometabolic disease, the DII has been applied in several emerging clinical contexts. The review notes evidence suggesting benefits of lower DII scores among cancer survivors, people with depression, and individuals with chronic inflammatory conditions. These findings point to potential roles for DII-informed assessment in diverse patient groups, although the evidence base in some areas is still developing and requires further confirmation.
To improve applicability and predictive value, methodological advances have been made. The energy-adjusted DII (E-DII) accounts for total energy intake when estimating dietary inflammatory potential. A pediatric adaptation, the C-DII, has been developed for use in children. These refinements broaden the index’s use across age groups and dietary assessment contexts and may enhance its comparability and performance in epidemiological and clinical studies.
While observational and associative data are consistent, the review emphasizes that causal relationships between dietary inflammatory scores and disease outcomes remain incompletely established. Limitations include reliance on nutritional assessment methods and biomarker endpoints that vary across studies, potential confounding in observational designs, and the relative paucity of long-term interventional trials using the DII as a target or endpoint. The review calls for well-designed, long-term interventional studies to clarify causality and to determine the DII’s prognostic significance in clinical practice.
The DII is presented as a useful conceptual and practical framework for assessing the relationship between diet and inflammation in both population and clinical settings. Current evidence supports its value in identifying dietary patterns associated with chronic inflammation and related diseases, and it may contribute to personalized nutrition strategies aimed at prevention and management of inflammation-related disorders. However, before the DII can be widely recommended as a clinical tool for prognosis or therapy guidance, further long-term intervention studies are needed to strengthen evidence for clinical utility and to establish whether modifying DII score leads to improved hard clinical outcomes.